Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Recurrence 20Leukemia 18Burkitt Lymphoma 18Lymphoma 17Neoplasms, Plasma Cell 13Lymphoma, Non-Hodgkin 13Nausea 12Lymphoma, Mantle-Cell 12Vomiting 11Waldenstrom Macroglobulinemia 10Breast Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, Follicular 9Immunoglobulin Light-chain Amyloidosis 8Lymphoma, B-Cell, Marginal Zone 7Hodgkin Disease 7Amyloidosis 7Smoldering Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myeloid, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6Prostatic Neoplasms 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4

Interventions

birtamimab 1Rosiglitazone 1Melphalan 1Magnetic Resonance Imaging 1Dexamethasone 1Control Groups 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Alzheimer Disease × Calcium Dobesilate × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡